UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 6.

Perger, L; Bürgi, U; Fattinger, K (2011). Pharmakotherapie bei Hyperthyreose - unerwünschte Arzneimittelwirkungen. Therapeutische Umschau, 68(6):303-308.

Hajda, J; Rentsch, K M; Gubler, C; Steinert, H; Stieger, B; Fattinger, K (2010). Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. European Journal of Pharmaceutical Sciences, 41(5):729-735.

Perger, L; Rentsch, K M; Kullak-Ublick, G A; Verotta, D; Fattinger, K (2009). Oral heroin in opioid-dependent patients: Pharmacokinetic comparison of immediate and extended release tablets. European Journal of Pharmaceutical Sciences, 36(4-5):421-432.

Halbsguth, U; Rentsch, K M; Eich-Höchli, D; Diterich, I; Fattinger, K (2008). Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. British Journal of Clinical Pharmacology, 66(6):781-791.

Fattinger, K; Roos, Malgorzata; Spiess, A; Vergères, P; Braunschweig, S; Kullak-Ublick, G A; Galeazzi, R L; Follath, F; Schaffner, A; Gasser, T; Meier-Abt, P J (2000). Die "Stiftung für Arzneimittelsicherheit" SAS/CHDM: Update 2000. Schweizerische Ärztezeitung (SÄZ), 81(42):2381-2384.

Fattinger, K; Cattori, V; Hagenbuch, B; Meier, P J; Stieger, B (2000). Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology, 32(1):82-86.

This list was generated on Tue Jul 25 07:11:59 2017 CEST.